Oncology

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

This week in Drug Discovery (4 – 8 May) 

News round-up for 4 – 8 May by Bruno Quinney, Content Team at DDW.  This week, the FDA has advanced an initiative to implement real-time clinical trials. Elsewhere, UCB has made headlines for through an acquisition and its cancer research venture.  The top stories:    FDA moves… Read More

#News

#Breast cancer #Clinical trial #Oncology #Ovarian cancer #Pancreatic cancer #Prostate cancer

Overcoming drug resistance with General Oncology

DDW Editor Reece Armstrong speaks to Jeff Glazier, CEO of General Oncology, about the challenges facing pancreatic cancer drug development and the company's activities in the space. RA: Why has pancreatic cancer remained so difficult to treat? JG: Pancreatic cancer is typically diagnosed at an advanced stage, is biologically aggressive, and rapidly develops resistance to therapy. Tumours are highly heterogeneous, both between… Read More

#Exclusive Content

Modern medical science laboratory
#Cancer Research Horizons #Cancer Research UK #Oncology #UCB

Cancer research alliance to advance ‘life-changing’ therapies 

A global initiative is set to leverage oncology expertise to advance a pipeline of novel cancer therapies.  Biopharmaceutical company UCB has announced a new multi-project alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons.   Under the new partnership, Cancer Research UK’s Centre… Read More

#Cancer Research #News

#Cancer research #Oncology #T cell #Tumour biology #Tumour microenvironment (TME)

The missing link in treating cancer

Eden Ben, CEO of Amorphical, and Dr Yigal Blum, CTO of Amorphical, argue that targeting the hostile tumour microenvironment is the key to effectively treating this aggressive cancer.  For years, the conversation around pancreatic cancer has focused on the tumour itself, the "broken" cells that won't stop growing. In 2026,… Read More

#Exclusive Content

#Drug discovery #Oncology #RadioMedix #Radiopharmaceuticals

The challenges and advancements in radiopharmaceuticals

DDW Editor Reece Armstrong speaks to Dr Ebrahim Delpassand, CEO of RadioMedix, about scaling access to radiopharmaceuticals and the company’s attempt to innovate in hard-to-treat cancers. RA: Could you discuss RAHA-100 and your goal of democratising access to the 212Pb isotope – why is this important?    ED: One of the central challenges in radiopharmaceutical targeted alpha therapy… Read More

#Exclusive Content

Cancer cells
#Oncology #Phase II trial #Repertoire Immune Medicines #Solid tumours

Repertoire initiates trial of T cell-targeted immune medicine

Repertoire Immune Medicines has dosed the first participant in a Phase I/II clinical trial of RPTR-1-201, a novel TCR bispecific therapy designed to treat advanced solid tumours.   The trial is being conducted at multiple clinical sites in the United States and Europe following clearance of Repertoire’s Investigational… Read More

#Cancer Research #Editor's Choice #News

T cells
#AI #Automation / robotics #Oncology #T cell engagers

How AI and robotics designed new cancer therapies

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Angus Sinclair, Chief Scientific Officer at LabGenius Therapeutics. LabGenius is a biotech using AI and robotics to design new cancer therapies, and in vivo efficacy data reveals… Read More

#Featured Podcasts #Podcasts

Proteomics
#Biotech #Oncology #Precision medicine #Proteomics

Nomic and Broad Clinical Labs to build proteomics platform 

Biotechnology company Nomic Bio has announced a partnership with Broad Clinical Labs (BCL) to build a scalable proteomics platform.  The organisations will look to integrate Nomic’s Omni 1000 solution into BCL’s existing capabilities to develop new application-specific solutions.   Based on nELISA technology, Nomic says Omni 1000 measures… Read More

#News

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

DDW Highlights: 21 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, key breakthroughs emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical… Read More

#Podcasts

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

This week in Drug Discovery (13 – 17 April) 

News round-up for 13 – 17 April by Bruno Quinney, Content Team at DDW.  This week, breakthroughs have emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical trial set up in the UK.  The top stories:    Novel therapy could slow tumour growth… Read More

#News

Ovarian cancer
#Corcept Therapeutics #Oncology #Ovarian cancer #Phase III trial

Combo treatment new SOC in platinum-resistant ovarian cancer

Corcept Therapeutics has shared final overall survival data from its pivotal Phase III ROSELLA trial of Lifyorli (relacorilant) combined with the chemotherapeutic agent nab-paclitaxel in patients with platinum-resistant ovarian cancer.  The results were shared in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) 2026… Read More

#Cancer Research #News #Trending News

Ovarian cancer cells
#GSK #Oncology #Ovarian cancer #Phase I trial

B7-H4-targeted ADC shows 62% response rate in ovarian cancer

The global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez) has shown confirmed objective response rates (cORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent or advanced endometrial cancer (EC).  Mocertatug rezetecan is a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. B7-H4… Read More

#Cancer Research #Editor's Choice #News

Cancer tumour
#Coiled Therapeutics #Oncology #Phase I trial #Solid tumours

First-in-class TACC3 inhibitor for solid tumours shows 80% CBR

Coiled Therapeutics has provided an update on its Phase I/II clinical trial evaluating AO-252, a first-in-class TACC3 inhibitor, in patients with advanced solid tumours.  According to the data, the transition to a Twice-Daily (BID) dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate (CBR), a… Read More

#Cancer Research #News

#Neurodegenerative disorders #Neuroscience #Oncology

This week in Drug Discovery (30 March – 3 April) 

News round-up for 30 March – 3 April by Diana Turner, Deputy Editor, DDW. This week, there have been a number of developments in neuroscience drug discovery. Elsewhere, a new treatment for platinum-resistant epithelial ovarian cancer has been approved in the US. The top stories: … Read More

#News

Bacteria in Petri dishes
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Covid-19 #mRNA #mRNA-based vaccines #Oncology #RNA

How drug discovery is tackling global health challenges

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Why more work is needed to fight antimicrobial resistance’. In the article, DDW Editor Reece Armstrong speaks to Professor… Read More

#Featured Podcasts